Lantern Total Stockholder Equity from 2010 to 2025

LTRN Stock  USD 5.07  0.23  4.34%   
Lantern Pharma Total Stockholder Equity yearly trend continues to be very stable with very little volatility. Total Stockholder Equity is likely to drop to about 34.6 M. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2019-12-31
Previous Quarter
30.9 M
Current Value
26.6 M
Quarterly Volatility
24.6 M
 
Covid
Check Lantern Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lantern Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 211.1 K, Interest Expense of 246.8 K or Selling General Administrative of 4.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.07. Lantern financial statements analysis is a perfect complement when working with Lantern Pharma Valuation or Volatility modules.
  
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Latest Lantern Pharma's Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Lantern Pharma over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Lantern Pharma's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lantern Pharma's overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Lantern Total Stockholder Equity Regression Statistics

Arithmetic Mean16,814,352
Coefficient Of Variation147.41
Mean Deviation21,127,053
Median(201,798)
Standard Deviation24,785,966
Sample Variance614.3T
Range71.8M
R-Value0.76
Mean Square Error275.2T
R-Squared0.58
Significance0.0006
Slope3,971,432
Total Sum of Squares9215.2T

Lantern Total Stockholder Equity History

202534.6 M
202447 M
202340.9 M
202256 M
202171.6 M
202019.7 M
2019943.3 K

About Lantern Pharma Financial Statements

Lantern Pharma investors utilize fundamental indicators, such as Total Stockholder Equity, to predict how Lantern Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Stockholder Equity47 M34.6 M
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.70)
Return On Assets
(0.28)
Return On Equity
(0.45)
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.